Attovia Therapeutics, Inc. (ATTO) Stock Statistics & Valuation Metrics

Attovia Therapeutics, Inc. has a market cap or net worth of $950.92M. The enterprise value is ―.

Attovia Therapeutics, Inc. has 45,651,260 shares outstanding. The number of shares has decreased by -2.65% in one year.

Attovia Therapeutics, Inc.’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -42.83%.

The current PE Ratio of Attovia Therapeutics, Inc. is ―. Attovia Therapeutics, Inc.’s PEG ratio is -0.44.

In the last 12 months, Attovia Therapeutics, Inc. had revenue of 1.35M and earned -60.63M in profits. Earnings per share was -1.42.

In the last 12 months, operating cash flow was -34.93M and capital expenditures -361.00K, giving a free cash flow of -35.29M billion.

Attovia Therapeutics, Inc. pays an annual dividend of $1.709, resulting in a dividend yield of 3.4%

Attovia Therapeutics, Inc. upcoming earnings date is Sep 2, 2026, After Close (Confirmed).

Attovia Therapeutics, Inc. as a current ratio of 14.20, with Debt / Equity ratio of 3.84%

In the past 12 months, Attovia Therapeutics, Inc. has paid 0.00 in taxes.

Attovia Therapeutics, Inc. EV to EBITDA ratio is -13.67, with an EV/FCF ratio of -14.75.

Attovia Therapeutics, Inc. has $115.13M in cash and marketable securities with $4.33M in debt, giving a net cash position of $110.81M billion.

Gross margin is -8.44%, with operating margin of -4974.74%, and net profit margin of -4490.89%.

The average price target for Attovia Therapeutics, Inc. is $39.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy